Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis

Experimental Cell Research

Volumn 252, Issue 1, 1999, Pages 144-153

  Naderi, Soheil ^a   Blomhoff, Rune ^a   Myklebust, June ^b   Smeland, Erlend B ^b   Erikstein, Bjørn ^c   Norum, Kaare R ^a   Blomhoff, Heidi Kiil ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NONE

Author keywords

Apoptosis; B lymphocytes; Cell cycle; Lovastatin; pRB; Proliferation

Indexed keywords

CYCLIN A; CYCLIN D; CYCLIN D2; CYCLIN E; IMMUNOGLOBULIN ANTIBODY; MEVINOLIN; PROTEIN P21; PROTEIN P27;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRENYLATION; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0033544022     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4608     Document Type: Article

References (54)

1. Hall A. The cellular function of small GTP-binding proteins. Science. 249:1990;635-639.
2. Harnett M. M., Klaus G. G. B. G protein regulation of receptor signalling. Immunology Today. 9:1988;315-320.
3. Maltese W. A. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. 4:1990;3319-3332.
4. Glomset J. A., Gelb M. H., Farnsworth C. C. Prenyl proteins in eukaryoticic cells: A new type of membrane anchor. TIBS. 15:1990;139-142.
5. Goldstein J. L., Brown M. S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
6. Monica K., Chen-Levy Z., Cleary M. L. Small G proteins are expressed ubiquitously in lymphoid cells and do not correspond to Bcl-2. Nature. 346:1990;189-191.
7. Graziadei L., Riabowol K., Bar-Sagi D. Co-capping of ras proteins with surface immunoglobulins in B lymphocytes. Nature. 347:1990;396-400.
8. Purkerson J. M., Parker D. C. Differential coupling of membrane Ig and CD40 to the extracellularly regulated kinase signaling pathway. J. Immunol. 160:1998;2121-2129.
9. Schafer W. R., Kim R., Sterne R., Thorner J., Kim S. H., Rine J. Genetic and pharmacological suppression of oncogenic mutations in Ras genes of yeast and humans. Science. 24:1989;379-385.
10. Cuthbert J. A., Lipsky P. E. Inhibition by 6-fluoromevalonate demonstrates that mevalonate or one of the mevalonate phosphates is necessary for lymphocyte proliferation. J. Biol. Chem. 265:1990;18568-18575.
11. Keyomarsi K., Sandoval L., Pardee A. B. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 51:1991;3602-3609.
12. Kip accumulation during the cell cycle. Science. 271:1996;1861-1864.
13. Poon R. Y. C., Toyoshima H., Hunter T. Redistribution of the CDK inhibitor p27 between different cyclin-CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol. Biol. Cell. 6:1995;1197-1213.
14. Reedquist K. A., Pope T. K., Roess D. A. Lovastatin inhibits proliferation and differentiation and causes apoptosis in lipopolysaccharide-stimulated murine B cells. Biochem. Biophys. Res. Commun. 211:1995;665-670.
15. Ghosh P. M., Mott G. E., Ghosh-Choudhury N., Radnik R. A., Stapleton M. L., Ghidoni I. J., Kreisberg J. I. Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultures mesangial cells. Biochim. Biophy. Acta. 1359:1997;13-24.
16. Rubins J. B., Greatens T., Kratzke R. A., Tan A. T., Polunovsky V. A., Bitterman P. Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Respir. Crit. Care Med. 157:1998;1616-1622.
17. Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell. Biol. 8:1996;805-814.
18. Morgan D. O. Principles of CDK regulation. Nature. 374:1995;131-134.
19. Weinberg R. A. E2F and cell proliferation: A world turned upside down. Cell. 85:1996;457-459.
20. Smeland E. B., Beiske K., Ohlsson R., Holte H., Ruud E., Blomhoff H. K., Jefferis R., Godal T. Activation of human B cells: Alternate option for initial triggering and effects of nonmitogenic concentrations of anti IgM antibodies on resting and activated cells. J. Immunol. 138:1987;3179-3184.
21. Blomhoff H. K., Smeland E. B., Erikstein B., Rasmussen A. M., Skrede B., Skjønsberg C., Blomhoff R. Vitamin A is a key regulator for cell growth, cytokine production and differentiation in normal B cells. J. Biol. Chem. 25:1992;23988-23992.
22. Lømo J., Blomhoff H. K., Beiske K., Stokke T., Smeland E. B. TGF-β and cyclic AMP promote apoptosis in resting human B lymphocytes. J. Immunol. 154:1995;1634-1643.
23. Lømo J., Smeland E. B., Krajewski S., Reed J., Blomhoff H. K. Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes. Cancer Res. 56:1996;40-43.
24. Lømo J., Blomhoff H. K., Jacobsen S. E., Krajewski S., Reed J., Smeland E. B. Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: Upregulation of Bcl-XL and Mcl-1. Blood. 89:1997;4415-4424.
25. Havel R., Eder H., Bragdon J. The distribution and chemical composition of ultrasentrifugalli separated lipoproteins in human serum. J. Clin. Invest. 34:1995;1345-1355.
26. Funderud S., Erikstein B., Åsheim H. C., Nustad K., Stokke T., Blomhoff H. K., Holte H., Smeland E. B. Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation. Eur. J. Immunol. 20:1990;201-206.
27. Farnsworth C. C., Gelb M. H., Glomset J. A. Identification of geranylgeranyl-modified proteins in Hela cells. Science. 247:1990;320-322.
28. Bijsterbosch M. K., Rigley K. P., Klaus G. G. B. Cross-linking of surface immunoglobulins in B lymphocytes induces both intracellular Ca++ release and Ca++ influx: Analysis with indo-1. Biochem. Biophys. Res. Commun. 137:1986;500-506.
29. Stokke T., Holte H., Steen H. B. In vitro and in vivo activation of B lymphocytes: A flow cytometric study of chromatic structure employing 7-actinomycin D. Cancer Res. 48:1988;6708-6714.
30. Skjønsberg C., Erikstein B. K., Smeland E. B., Lie S. O., Funderud S., Beiske K., Blomhoff H. K. Interleukin-7 differentiates a subgroup of acute lymphoblastic leukemias. Blood. 77:1991;2445-2450.
31. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
32. 2. Mol. Cell. Biol. 16:1996;762-770.
33. Matsushime H., Quell D. E., Shurtleff S. A., Shibuya M., Sherr C. J., Kato J. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14:1994;2066-2076.
34. Gorczyca W., Bigman K., Mittelman A., Ahmed T., Gong J., Melamed M. R., Darzynkiewicz Z. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia. 7:1993;659-670.
35. Swat W., Idnatowicz L., Kisielow P. Detection of apoptosis of immature CD4+8+ thymocytes by flow cytometry. J. Immunol. Methods. 137:1991;79-87.
36. Jurgensen C. H., Ambrus J. L. Jr., Fauci A. S. Production of B cell growth factor by normal human B cells. J. Immunol. 136:1986;4542-4547.
37. Holte H., Torjesen P., Blomhoff H. K., Ruud E., Funderud S., Smeland E. B. Cyclic AMP has the ability to influence multiple events during B cell stimulation. Eur. J. Immunol. 18:1988;1359-1366.
38. Smeland E. B., Blomhoff H. K., Holte H., Ruud E., Beiske K., Funderud S., Godal T., Ohlsson R. Transforming growth factor type β (TGF β) inhibits G1 to S transition, but not activation of human B lymphocytes. Exp. Cell Res. 171:1987;213-222.
39. Rivard N., Allemain G., Bartek J., Poussegur J. Abrogation of p27 Kip1 by cDNA antisense suppresses quiescence (Go state) in fibroblasts. J. Biol. Chem. 271:1996;18337-18341.
40. Gray-Bablin J., Rao S., Keyomarsi K. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res. 57:1997;604-609.
41. Habenicht A. J. R., Glomset J. A., Ross R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J. Biol. Chem. 255:1980;5134-5140.
42. Schmidt R. A., Schneider C. J., Glomset J. A. Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins. J. Biol. Chem. 259:1984;10175-10180.
43. Wolda S. L., Glomset J. A. Evidence for modification of lamin B by a product of mevalonic acid. J. Biol. Chem. 263:1988;5997-6000.
44. Schaber M. D., O'Hara M. B., Garsky V. M., Mosser S. D., Bergstrom J. D., Moores S. L., Marshall M. S., Friedman P. A., Dixon R. A. F., Gibbs J. B. Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase. J. Biol. Chem. 265:1990;14701-14704.
45. Casey P. J., Solski P. A., Der C. J., Buss J. E. Ki-ras is modified by a farnesyl isoprenoid. Proc. Natl. Sci. USA. 86:1989;8323-8327.
46. Zetterberg A., Larsson O., Wiman K. G. What is the restriction point. Curr. Opin. Cell Biol. 7:1995;835-842.
47. WAF1/CIP1/SDI1 in a p53-independent manner. J. Biol. Chem. 43:1997;27224-27229.
48. McGuire T. F., Sebti S. M. Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity. Oncogene. 14:1997;305-312.
49. Crick D. C., Waechter C. J., Andres D. A. Utilization of geranylgeraniol for protein prenylation in C6 glial cells. Biochem. Biophys. Acta. 205:1994;955-961.
50. Vogt A., Qian Y., McGuire T. F., Hamilton A. D., Sebti S. M. Protein geranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene. 13:1996;1991-1999.
51. Smeland E. B., Blomhoff H. K., Ohlsson R., Davies C. D., Funderud S., Boye E. Transcription of protooncogenes during stimulation of normal human B lymphocytes. Eur. J. Immunol. 18:1988;1847-1850.
52. Kip and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem. 272:1997;13-16.
53. Waf1/Cip 1. Nature. 394:1998;295-298.
54. ras but does not affect their function. Cancer Res. 55:1995;3295-3304.